Hospital Pharmacies held a 60.2% share of the intravenous immunoglobulin market in 2025, reflecting their central role in administering high-cost infusion therapies that require close clinical oversight, inventory control, and coordinated patient management. Their leadership is maintained through the fact that intravenous immunoglobulin is commonly used in hospital-based treatment settings where dosing, monitoring, and adverse event management can be handled within established care pathways. This keeps Hospital Pharmacies closely tied to prescribing specialists and acute care workflows, reinforcing their leading share in the intravenous immunoglobulin market.

Specialty Pharmacies are emerging as the fastest-growing channel in the intravenous immunoglobulin market because they are better aligned with the rising need for coordinated long-term therapy management outside traditional inpatient settings. Their momentum is backed by their ability to handle complex biologics distribution, reimbursement navigation, and patient support services in a more focused way than broader pharmacy channels. As treatment models increasingly emphasize continuity of care and streamlined access for chronic immune-related conditions, Specialty Pharmacies are gaining ground relative to alternatives that are less specialized in managing these therapy requirements.

Application Segment Analysis: Immunodeficiency Diseases (Largest Segment) vs Kawasaki Disease (Fastest-Growing Segment)

By 2025, Immunodeficiency Diseases accounted for a 21.76% share of the intravenous immunoglobulin market, backed by the established role of IVIG as a core therapy in patients who require ongoing immune replacement or modulation. This segment’s leadership is rooted in the recurrent and clinically necessary nature of treatment, which creates steady demand across diagnosed patient populations and makes utilization less episodic than in many other applications. That consistent treatment need helps Immunodeficiency Diseases retain the leading share in the intravenous immunoglobulin market.

Kawasaki Disease represents the fastest-growing application in the intravenous immunoglobulin market due to the urgent treatment setting in which IVIG is used and the strong dependence on timely intervention to reduce serious complications. Growth in this segment is being shaped by increased recognition and diagnosis, which can translate quickly into treatment demand because IVIG is a well-established part of care once the condition is identified. Compared with applications where use may be more prolonged but stable, Kawasaki Disease is gaining momentum through faster expansion in identified case management and treatment initiation.